BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

April 15, 2021

View Archived Issues
Test tubes

C2i Genomics raises $100M in series B to advance residual cancer detection technology

Anyone who has had a malignant tumor removed knows the anxiety that follows. Did any traces of cancer remain, and if it returns, will doctors catch it before it’s too late? To reduce the uncertainty and improve patient outcomes, C2i Genomics Inc. has raised a $100 million series B funding round led by Casdin Capital to advance software that is 100 times more sensitive in detecting residual disease than legacy technologies. Read More
OCT image

FDA grants breakthrough device designation for Perimeter’s AI-assisted OCT

Just six weeks after receiving FDA 510(k) clearance for its optical coherence tomography (OCT) imaging system (v2.1), Perimeter Medical Imaging AI Inc. received breakthrough device designation from the FDA for its next-gen product, the OCT imaging system with integrated artificial intelligence (AI). Read More
US-budget-spending-money.png

Becerra: ARPA-H a translational research office, but some see redundancy

The Biden administration’s fiscal 2022 budget proposal included an allocation for an office described as the Advanced Research Projects Agency – Health, or ARPA-H, which would receive $6.5 billion as part of the National Institutes of Health. Read More
3-24-electrocore-gammacore-sapphire.png

Canadian approval of headache therapy more validation for Electrocore, new business model for RSK Medical

TORONTO – For Scott Kadwell, president of Markham, Ontario-based RSK Medical Inc., the distributor tagged to sell the Health Canada approved Gammacore Sapphire, the device represents “a shift from a business to business to a direct-to-consumer business model.” For Rockaway, N.J.’s Electrocore Inc. which developed the self-administered technology, it’s one more regulator to have greenlighted the FDA cleared, CE-marked device for treating intractable migraine and cluster headache. Read More
Illustration of pill being analyzed

Stonewise raises $100M in B and B+ rounds to advance AI-enabled drug discovery

HONG KONG – Beijing Stonewise Technology Co. Ltd., a med-tech firm that uses artificial intelligence (AI) to aid in the discovery of small molecule drugs, closed series B and B+ financing rounds that added $100 million to its pocket. The company intends to use the proceeds to upgrade its AI-enabled drug discovery platform. Read More

Appointments and advancements for April 15, 2021

New hires and promotions in the med-tech industry, including: 100 Plus, Angiosoma, Butterfly Network, Clover Health, Inflammatix, Nemaura, Neopenda, Revibe, Suralign. Read More

Financings for April 15, 2021

Med-tech firms raising money in public or private financings, including: Imageens, Medable, Rapha Capital Management, Revibe Technologies, Spectral Medical. Read More

In the clinic for April 15, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abiomed, Castle Biosciences, Gynesonics, Nanoview Biosciences. Read More

Other news to note for April 15, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Agilent Technologies, ATMPS, Biolq, Biostem Technologies, Blue Cross Blue Shield of Massachusetts, Canon Medical, Cloud Dx, Consonance-HFW, D8 Holdings, EBR Systems, Emblemhealth, Fionet, Geninus, Helixrus, Implicity, Mindmaze Healthcare, MLU Services, Ori Biotech, Powerdot, PPD, Procept Biorobotics, Raysearch, Relay Medical, Resolution Bioscience, Rosalind, Soliton, Surrozen, Therabody, Thermo Fisher Scientific, Vicarious Surgical. Read More

Regulatory actions for April 15, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Perimeter Medical Imaging AI. Read More

Regulatory front for April 15, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA reverses HHS premarket notification exemptions; ITC will check findings for Zimmer/Heraeus dispute. Read More

BioWorld MedTech’s Diagnostics Extra for April 15, 2021

Keeping you up to date on recent developments in diagnostics, including: Imbalance in gum bacteria linked to Alzheimer-related protein in healthy adults; Tiny device monitors deep-tissue oxygen. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing